Posted on September 15th, 2011 by
Biopharmaceutical company Oxigene Inc. (OXGN) presented data that showed the company's zybrestat treatment helped increase the one-year survival rate of patients with larger anaplastic thyroid cancer tumors…The company said the data was derived from a comparison between the results of Oxigene's aggregate data from five independent Phase 1 and Phase 2 trials using zybrestat to treat patients with anaplastic thyroid cancer. Key findings include the fact that 13 patients, or 9.7% of all patients treated at the Mayo Clinic, survived one year or longer.
Wall Street Journal, 9/15/11
You must be logged-in to the site to post a comment.